Sensitization for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by the Chemopreventive Agent Resveratrol

Cancer Research

Volumn 64, Issue 1, 2004, Pages 337-346

  Fulda, Simone ^a   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CISPLATIN; CYCLOHEXIMIDE; DOXORUBICIN; ETOPOSIDE; LIGAND; MIMOSINE; NOCODAZOLE; PROTEIN P21; PROTEIN P53; RESVERATROL; SURVIVIN; THYMIDINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ZVAD FMK;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PREVENTION; CELL CYCLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; FIBROBLAST; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; TUMOR CELL; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; BRAIN NEOPLASMS; BREAST NEOPLASMS; CASPASES; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CYSTEINE PROTEINASE INHIBITORS; DNA PRIMERS; FEMALE; HUMANS; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STILBENES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1642576201     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1656     Document Type: Article

References (49)

1. Peto, J. Cancer epidemiology in the last century and the next decade. Nature (Lond.), 411: 390-395, 2001.
2. Ponder, B. A. Cancer genetics. Nature (Lond.), 411: 336-341, 2001.
3. Lowe, S. W., and Lin, A. W. Apoptosis in cancer. Carcinogenesis (Lond.), 21: 485-495, 2000.
4. Debatin, K. M., Poncet, D., and Kroemer, G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene, 21: 8786-8803, 2002.
5. Hengartner, M. O. The biochemistry of apoptosis. Nature (Lond.), 407: 770-777, 2000.
6. Herr, I., and Debatin, K. M. Cellular stress response and apoptosis in cancer therapy. Blood, 98: 2603-2614, 2001.
7. Johnstone, R. W., Ruefli, A. A., and Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108: 153-164, 2002.
8. Fulda, S., Susin, S. A., Kroemer, G., and Debatin, K. M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res., 58: 4453-4460, 1998.
9. Fulda, S., and Debatin, K. M. IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene, 21: 2295-2309, 2002.
10. Fulda, S., Kufer, M. U., Meyer, E., van Valen, F., Dockhorn-Dworniczak, B., and Debatin, K. M. Sensitization for death receptor- or drug-induced apoptosis by reexpression of caspase-8 through demethylation or gene transfer. Oncogene, 20: 5865-5877, 2001.
11. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer, 2: 420-430, 2002.
12. Walczak, H., and Krammer, P. H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res., 256: 58-66, 2000.
13. Thornberry, N., and Lazebnik, Y. Caspases: enemies within. Science (Wash. DC), 281: 1312-1316, 1998.
14. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J., 17: 1675-1687, 1998.
15. Kroemer, G., and Reed, J. C. Mitochondrial control of cell death. Nat. Med., 6: 513-519, 2000.
16. van Loo, G., Saelens, X., van Gurp, M., MacFarlane. M., Martin, S. J., and Vandenabeele, P. The role of mitochondrial factors in apoptosis: a Russian roulette with more, than one bullet. Cell Death Differ., 9: 1031-1042, 2002.
17. Wajant, H., Pfizenmaier, K., and Scheurich, P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis, 7: 449-459, 2002.
18. Igney, F. H., and Krammer, P. H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer, 2: 277-288, 2002.
19. Fulda, S., Meyer, E., and Debatin, K. M. Overexpression of Bcl-2 inhibits TRAIL-induced apoptosis. Oncogene, 21: 2283-2294, 2002.
20. Salvesen, G. S., and Duckett, C. S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell. Biol., 3: 401-410, 2002.
21. Altieri, D. C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer, 3: 46-54, 2003.
22. Goyal, L. Cell death inhibition: keeping caspases in check. Cell, 104: 805-808, 2001.
23. Fulda, S., Wick, W., Weller, M., and Debatin, K. M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med., 8: 808-815, 2002.
24. Gusman, J., Malonne, H., and Atassi, G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis (Lond.), 22: 1111-1117, 2001.
25. Cal, C., Garban, H., Jazirehi, A., Yeh, C., Mizutani, Y., and Bonavida, B. Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr. Med. Chem. Anti-Canc. Agents, 3: 77-93, 2003.
26. Belloc, F., Belaud-Rotureau, M. A., Lavignolle, V., Bascans, E., Braz-Pereira, E., Durrieu, F., and Lacombe, F. Flow cytometry detection of caspase 3 activation in preapoptotic leukemic cells. Cytometry, 40: 151-160, 2000.
27. Fukuda, S., and Pelus, L. M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood, 98: 2091-2100, 2001.
28. Olie, R. A., Simoes-Wust, A. P., Baumann, B., Leech, S. H., Fabbro, D., Stahel, R. A., and Zangemeister-Wittke, U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res., 60: 2805-2809, 2000.
29. Mahotka, C., Wenzel, M., Springer, E., Gabbert, H. E., and Gerharz, C. D. Survivin-AEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res., 59: 6097-6102, 1999.
30. Glaser, T., Wagenknecht, B., and Weller, M. Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene, 20: 4757-4767, 2001.
31. 34 by flavopiridol enhances tumor cell apoptosis. Cancer Res., 63: 230-235, 2003.
32. Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J., and Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem., 277: 3247-3257, 2002.
33. Kim, B., and Feldman, E. L. Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J. Biol. Chem., 277: 27393-27400, 2002.
34. 1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle, 1: 82-89, 2002.
35. Gartel, A. L., and Tyner, A. L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther., 1: 639-649, 2002.
36. Hingorani, R., Bi, B., Dao, T., Bae, Y., Matsuzawa, A., and Crispe, I. N. CD95/Fas signaling in T lymphocytes induces the cell cycle control protein p21cip-1/WAF-1, which promotes apoptosis. J. Immunol., 164: 4032-4036, 2000.
37. Pucci, B., Kasten, M., and Giordano, A. Cell cycle and apoptosis. Neoplasia, 2: 291-299, 2000.
38. Smith, D. M., Gao, G., Zhang, X., Wang, G., and Dou, Q. P. Regulation of tumor cell apoptotic sensitivity during the cell cycle. Int. J. Mol. Med., 6: 503-507, 2000.
39. Sax, J. K., Dash, B. C., Hong, R., Dicker, D. T., and El-Deiry, W. S. The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). Cell Cycle, 1: 90-96, 2002.
40. Goke, R., Goke, A., Goke, B., El-Deiry, W. S., and Chen, Y. Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion, 64: 75-80, 2001.
41. Manna, S. K., Mukhopadhyay, A., and Aggarwal, B. B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol., 164: 6509-6519, 2000.
42. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert. A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Investig., 104: 155-162, 1999.
43. Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., Hooley, J., Sherwood, S., Pai, R., Leung, S., Khan, L., Gliniak, B., Bussiere, J., Smith, C. A., Strom, S. S., Kelley, S., Fox, J. A., Thomas, D., and Ashkenazi, A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med., 7: 383-385, 2001.
44. Nagane, M., Huang, H. J., and Cavenee, W. K. The potential of TRAIL for cancer chemotherapy. Apoptosis, 6: 191-197, 2001.
45. Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R., G., Rauch, C. T., Schuh, J. C., and Lynch, D. H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med., 5: 157-163, 1999.
46. Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Marsters, S. A., and Koeppen, H. Monoclonal antibodies to death receptor 4. J. Immunol., 166: 4891-4898, 2001.
47. Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., and Zhou, T. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med., 7: 954-960, 2001.
48. Bhat, K. P., and Pezzuto, J. M. Cancer chemopreventive activity of resveratrol. Ann. N. Y. Acad. Sci., 957: 210-229, 2002.
49. Deveraux, Q. L., and Reed, J. C. IAP family proteins: suppressors of apoptosis. Genes Dev., 13: 239-252, 1999.